Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
Serina Therapeutics entered a development partnership with Gannet BioChem to support the manufacturing and scale-up of SER-252, its investigational therapy for advanced Parkinson's disease. The collaboration leverages Gannet's expertise in process development as Serina advances SER-252 into clinical development following its recent FDA IND clearance.
Key figures
- Drug Name
- SER-252
- Phase Of Trial
- clinical development
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.